NEW YORK (GenomeWeb News) – Strategic Diagnostics yesterday reported first-quarter revenue growth of 8 percent and swung from a profit to a slight loss.

 

For the three-month period ended March 31, the Newark, Del.-based firm reported revenues of $7.2 million, up from $6.6 million in the first quarter of 2007. The firm said that primary growth drivers for the quarter were its food pathogen product sales, which climbed 36 percent year over year, and its antibody products, which increased 15 percent.